Chronic Urticaria Market

Market Overview:

The 7 major chronic urticaria markets reached a value of US$ 14.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 32.4 Million by 2034, exhibiting a growth rate (CAGR) of 7.97% during ​2024-2034​.

The chronic urticaria market has been comprehensively analyzed in IMARC's new report titled "Chronic Urticaria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2024-2034​". Chronic urticaria is a common dermal disorder characterized by severely inflamed, well-encircled, swollen welts with sizes that range from a few millimeters to several centimeters or wider. The secretion of excessive quantities of histamine and other inflammatory mediators in the skin causes this disorder. The indications of chronic urticaria usually begin on the affected person's skin. These include clusters of welts that can appear on any body part. Further symptoms encompass welts that differ in size and form, as well as appear or disappear repetitively, itchiness that can be strenuous, a painful soreness all around the eyes, cheeks, and lips, flares caused by high temperatures, workouts, or strain, and clinical signs that last longer than six weeks and recur frequently, etc. The diagnosis of chronic urticaria is primarily clinical. The doctor may review the patient's medical history and ask questions regarding when and where the rash initially appeared, any genetic history of urticaria, and the patient's current skin condition. A physical examination that includes evaluating the pulse rate and characterizing and identifying present lesions and their severity with the help of a skin biopsy is required for further diagnosis. To rule out any underlying issues, the doctor may also examine the eyes, ears, nose, throat, lymphoid tissue, stomach, and locomotor system.

The rising prevalence of allergic disorders and infections owing to several associated triggering factors, such as diet, alcohol, heat and friction, mental stress, etc., is primarily driving the global chronic urticaria market. In addition to this, the growing incidences of autoimmune ailments, such as celiac disease, rheumatoid arthritis, Type 1 diabetes, etc., which increase the risk of chronic urticaria are also positively influencing the market growth. Moreover, the introduction of advanced validated instruments that can quantify the severity of the ailment is further propelling the market growth. Besides this, the governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness regarding the significant psychosocial effects of chronic urticaria, especially stigmatization. This, in turn, is also acting as another growth-inducing factor. Additionally, several key players are making extensive investments in R&D activities to evaluate the safety and efficacy, mechanism of action, and dosing of biologics, which is further bolstering the global market. Numerous other factors, including the emerging popularity of second-generation antihistamines, such as fexofenadine HCl, and the development of preventive and pharmacological approaches to control the disabling symptoms suffered by patients, are expected to drive the global chronic urticaria market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic urticaria market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic urticaria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic urticaria market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: ​2018-2023​
• Market Forecast: ​2024-2034​
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic urticaria market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic urticaria market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic urticaria marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic urticaria market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic urticaria market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic urticaria market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the size of the chronic urticaria patient pool (​2018-2023​) across the seven major markets?
• What would be the forecasted patient pool (​2024-2034​) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic urticaria ?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Urticaria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic urticaria drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic urticaria market?